Telomerase mRNA detection in serum of patients with prostate cancer

Urologic Oncology: Seminars and Original Investigations

Volumn 31, Issue 2, 2013, Pages 205-210

  Dalle Carbonare, Luca ^a   Gasparetto, Adriano ^a   Donatelli, Luca ^a   Dellantonio, Alessandra ^a   Valenti, Maria Teresa ^a  

^a UNIVERSITY OF VERONA   (Italy)

Author keywords

Prostate; RNA; RT real time PCR; Serum

Indexed keywords

MESSENGER RNA; TELOMERASE;

ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; MALE; METABOLIC DISORDER; PRIORITY JOURNAL; PROSTATE CANCER; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

AGED; AGED, 80 AND OVER; HUMANS; MALE; PROSTATIC NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TELOMERASE; TUMOR MARKERS, BIOLOGICAL;

EID: 84875267730     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2010.12.017     Document Type: Article

References (43)

1. Troyer D.A., Mubiru J., Leach R.J., et al. Promise and challenge: Markers of prostate cancer detection, diagnosis, and prognosis. Dis Markers 2004, 20:117-128.
2. Nelson M.A., Porterfield B.W., Jacobs E.T., et al. Selenium and prostate cancer prevention. Semin Urol Oncol 1999, 17:91-96.
3. Chiong E., Wong A.F., Chan Y.H., et al. Review of clinical manifestations of biochemically-advanced prostate cancer cases. Asian J Surg 2005, 28:202-206.
4. Lilleby W., Fosså S.D., Waehre H.R., et al. Long-term morbidity and quality of life in patients with localized prostate cancer undergoing definitive radiotherapy or radical prostatectomy. Int J Radiat Oncol Biol Phys 1999, 43:735-743.
5. Humphrey P.A. Gleason grading and prognostic factors in carcinoma of the prostate. Mod Pathol 2004, 17:292-306.
6. Allsbrook W.C., Mangold K.A., Yang X., et al. The Gleason grading system: An overview. J Urol Pathol 1999, 10:141-157.
7. Kattapuram S.V., Phillips W.C. Paget's disease of bone mimicking metastases. J Can Assoc Radiol 1982, 33:239-245.
8. Mundy G.R. Mechanisms of bone metastasis. Cancer 1997, 80:1546-1556.
9. Peters J.L., Fairney A., Kyd P., et al. Bone loss associated with the use of LHRH agonists in prostate cancer. Prostate Cancer Prostatic Dis 2001, 4:161-166.
10. Diamond T.H., Higano C.S., Smith M.R., et al. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: Recommendations for diagnosis and therapies. Cancer 2004, 100:892-899.
11. Osborn J.L., Getzenberg R.H., Trump D.L. Spinal cord compression in prostate cancer. J Neurooncol 1995, 23:135-147.
12. Huddart R.A., Rajan B., Law M., et al. Spinal cord compression in prostate cancer: Treatment outcome and prognostic factors. Radiother Oncol 1997, 44:229-236.
13. Sutton M.A., Watkins H.L., Green L.K., et al. Intracranial metastases as the first manifestation of prostate cancer. Urology 1996, 48:789-793.
14. Fervenza F.C., Wolanskyj A.P., Eklund H.E., et al. Brain metastasis: An unusual complication from prostatic adenocarcinoma. Mayo Clin Proc 2000, 75:79-82.
15. Chang J.M., Lee H.J., Lee S.E., et al. Unusual tumours involving the prostate: Radiological-pathological findings. Br J Radiol 2008, 81:907-915.
16. Shah S.K., Lui P.D., Baldwin D.D., et al. Urothelial carcinoma after external beam radiation therapy for prostate cancer. J Urol 2006, 175:2063-2066.
17. Scully J.M., Uno J.M., McIntyre M., et al. Radiation-induced prostatic sarcoma: A case report. J Urol 1990, 144:746-748.
18. Mazzucchelli R., Lopez-Beltran A., Cheng L., et al. Rare and unusual histological variants of prostatic carcinoma: Clinical significance. BJU Int 2008, 102:1369-1374.
19. Consensus statement: Guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 1997, 37:1035-1041. American Society for Therapeutic Radiology and Oncology Consensus Panel.
20. Bensalah K., Lotan Y., Karam J.A., et al. New circulating biomarkers for prostate cancer. Prostate Cancer Prostatic Dis 2008, 11:112-120.
21. Shariat S.F., Scardino P.T., Lilja H. Screening for prostate cancer: An update. Can J Urol 2008, 15:4363-4374.
22. Zhou H., Xu W., Qian H., et al. Circulating RNA as a novel tumor marker: An in vitro study of the origins and characteristics of extracellular RNA. Cancer Lett 2008, 259:50-60.
23. Ferracin M., Veronese A., Negrini M. Micromarkers: miRNAs in cancer diagnosis and prognosis. Expert Rev Mol Diagn 2010, 10:297-308.
24. Henegan H.M., Miller N., Lowery A.J., et al. Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Ann Surg 2010, 251:499-505.
25. Ng E.K., Chong W.W., Jin H., et al. Differential expression of microRNAs in plasma of patients with colorectal cancer: A potential marker for colorectal cancer screening. Gut 2009, 58:1375-1381.
26. Fleischhacker M. Biology of circulating mRNA still more questions than answers. Ann NY Acad Sci 2006, 1075:40-49.
27. Bachand F., Triki I., Autexier C. Human telomerase RNA-protein interactions. Nucleic Acids Res 2001, 29:3385-3393.
28. Yan P., Coindre J.M., Benhattar J., et al. Telomerase activity and human telomerase reverse transcriptase mRNA expression in soft tissue tumors: Correlation with grade, histology, and proliferative activity. Cancer Res 1999, 59:3166-3170.
29. Miura N., Shiota G., Nakagawa T., et al. Sensitive detection of hTERT mRNA in the serum of patients with hepatocellular carcinoma. Oncology 2003, 64:430-434.
30. Novakovic S., Hocevar M., Zgajnar J., et al. Detection of telomerase RNA in the plasma of patients with breast cancer, malignant melanoma, or thyroid cancer. Oncol Rep 2004, 11:245-252.
31. Li Y.R., Wu J.M., Wang L., et al. Human telomerase reverse transcriptase expression and its clinical significance in laryngeal squamous cell carcinoma. Acta Otolaryngol 2005, 25:409-414.
32. Stewart S.A., Weinberg R.A. Telomerase and human tumorigenesis. Semin Cancer Biol 2000, 10:399-406.
33. Masutomi K., Hahn W.C. Telomerase and tumor genesis. Cancer Lett 2003, 194:163-172.
34. Zou Y., Misri S., Shay J.W., et al. Altered states of telomere deprotection and the two-stage mechanism of replicative aging. Mol Cell Biol 2009, 29:2390-2397.
35. Orlando C., Gelmini S. Telomerase in endocrine and endocrine-dependent tumors. J Steroid Biochem Mol Biol 2001, 78:201-214.
36. Mabruk M.J., O'Flatharta C. Telomerase: Is it the future diagnostic and prognostic tool in human cancer?. Expert Rev Mol Diagn 2005, 5:907-916.
37. Muller M. Telomerase: Its clinical relevance in the diagnosis of bladder cancer. Oncogene 2002, 21:650-655.
38. Maitra A., Rathi A., Gazdar A.F., et al. Expression of the RNA component of human telomerase (hTR) in ThinPrep preparations from bladder washings. Cancer 2001, 93:73-79.
39. Hahn W.C. Role of telomeres and telomerase in the pathogenesis of human cancer. J Clin Oncol 2003, 21:2034-2043.
40. Dasí F., Martínez-Rodes P., March J.A., et al. Real-time quantification of human telomerase reverse transcriptase mRNA in the plasma of patients with prostate cancer. Ann NY Acad Sci 2006, 1075:204-210.
41. Ellis W.J., Pfitzenmaier J., Colli J., et al. Detection and isolation of prostate cancer cells from peripheral blood and bone marrow. Urology 2003, 61:277-281.
42. Moreno J.G., Miller M.C., Gross S., et al. Circulating tumor cells predict survival in patients with metastatic prostate cancer. Urology 2005, 65:713-718.
43. Chen B.T., Loberg R.D., Neeley C.K., et al. Preliminary study of immunomagnetic quantification of circulating tumor cells in patients with advanced disease. Urology 2005, 65:616-621.